Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is a two-armed randomized cross-over comparison of leakage with nasal prongs and nasal mask interface in newborn infants treated with CPAP, born after 28 weeks of gestational age. For infants with an interface leakage, the trial also includes an observational part evaluating simple measures to reduce leakage.
The study will be carried out in the Karolinska University Hospital Stockholm and in the Östersund Hospital.
The study will recruit a total of 50 infants receiving CPAP for respiratory support at the Karolinska University Hospital and the Östersund Hospital. The infant should be stable and not in major respiratory distress. Consent from the parents will be obtained before enrolment.
The included infants should have stable spontaneous breathing and be older than 28 weeks (corrected age) at the time of enrolment. The reason for respiratory failure and CPAP treatment is not relevant for study purposes. If an infant cannot participate in the study at a given time, he or she can be enrolled later. A child can only participate once.
The primary outcome is leakage. This is recorded using equipment for measuring air flow during CPAP treatment. Measurement of leakage is first performed for one interface and then the next (cross-over). The interface order is randomized. The leakage will be measured after a few minutes of stabilization (part 1). If there is leakage, a few simple measures to reduce the leakage will be evaluated (part 2). The second part will approximately add 10-20 minutes and includes simple measures such as adjusting the nasal mask, closing the mouth, changing the position or changing the size of nasal mask/prongs. Part 1 and part 2 are then repeated for the next interface. If the child shows signs of distress or agitation the measurement will be paused or stopped.
Part 1: The CPAP system with the randomized interface (nasal mask or nasal prongs) is applied and adjusted by experienced NICU staff. The staff is blinded for the outcome variable, leakage. The choice of size and other adjustments are guided by clinical experience and not by protocol. The NICU staff is not allowed to participate in the explorative part where measures to reduce leakage are evaluated. This precaution is to avoid staff learning what adjustments affect leakage and influence care of infants enrolled at a later stage.
Part 2: In this part the investigators can evaluate the effect of simple measures to minimize the leakage. The level of leakage is displayed on a screen. Examples of measures are; closing the mouth of the infant, adjusting straps, adjusting position and changing the size of the interface. Not every child will undergo all measures to reduce leakage, since the aim of this explorative part is to explore ways to reduce leakage.
It is estimated that these tests and measures will take 15-60 minutes per child. No other measurements or follow-up is planned. No blood samples will be collected or analysed.
The study will collect information on the infant and the birth. This includes birth weight, gestational age at birth, gender, previous respiratory support and medical history.
The main outcome variable is absolute leakage (via mouth or via CPAP interface). Other collected variables are oxygen saturation, respiratory rate, inspired oxygen concentration, apneas, heart rate, if the infant is awake/asleep or in distress. Safety variables include skin irritation or damage of the nose caused by the interface, instability or deterioration of respiration or circulation, problems with the equipment or other adverse events. The investigation can be stopped immediately in the case of distress or instability. The study is, as far as the investigators know, the first one of its kind. The air flow meters do not affect the CPAP system and use a technique that measures the total leakage in L/min. These improvements have been emphasized in previous studies. The study follows GCP (good clinical practice) standards and The Helsinki declaration.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Nasal mask interface | Active Comparator | The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention. |
|
| Nasal prongs interface | Active Comparator | The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nasal mask interface | Device | Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size. |
| Measure | Description | Time Frame |
|---|---|---|
| Leakage in the CPAP system | Measurement of absolute leakage (at interface or mouth) using flowmeters connected to the CPAP device in flow through position (L/min, 30 seconds recording) | 0-60 min |
| Measure | Description | Time Frame |
|---|---|---|
| Inspired oxygen level (FiO2) | FiO2 level and adjustments needed to maintain pre-intervention baseline peripheral oxygen saturation (SpO2 target range according to local guidelines) | 0-60 min |
| Level of CPAP support (cmH2O) |
| Measure | Description | Time Frame |
|---|---|---|
| Safety variable: Desaturation during measurement | Desaturation (SpO2) from baseline requiring treatment or adjustment, during manipulation or leakage measurement. | 0 to competition of measurement (maximum 3 hours) |
| Safety variable: Apneas during measurement |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Baldvin Jonsson, MD, PhD | Karolinska Institutet | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Östersund hospital | Östersund | Jämtland County | 83143 | Sweden | ||
| Karolinska University Hospital, Neonatology department |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36261145 | Derived | Gunnarsdottir K, Falk M, Baldursdottir S, Donaldsson S, Jonsson B, Drevhammar T. Do newborn infants exhale through the CPAP system? Secondary analysis of a randomised cross-over trial. Arch Dis Child Fetal Neonatal Ed. 2023 May;108(3):232-236. doi: 10.1136/archdischild-2022-324462. Epub 2022 Oct 19. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D053120 | Respiratory Aspiration |
| D047928 | Premature Birth |
| ID | Term |
|---|---|
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Main study design: Two armed randomized cross-over comparison of leakage for two interfaces. The trial also investigates simple measures to reduce leakage (observational)
Not provided
Not provided
Not provided
Not provided
| Nasal prongs interface | Device | Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size. |
|
CPAP level and adjustments needed to maintain pre-intervention baseline peripheral oxygen saturation (SpO2 target range according to local guidelines)
| 0-60 min |
| Peripheral oxygen saturation (SpO2) | Deviations from baseline and changes requiring adjustment of respiratory support (Outcome 2 and 3) | 0-60 min |
| Measurement completion possible (yes/no) | The number of infants (ratio of total included patients) where measurement of leakage could be determined (on first or more attempts) | 0-60 min |
| Effect of simple measures to reduce leakage (L/min) | Lowest level of recorded level of leakage obtainable using simple measures to reduce leakage, guided by leakage monitoring equipment (L/min and measures used to achieve reduction) | 0-60 min |
Apneas requiring treatment or adjustment, during manipulation or leakage measurement.
| 0 to competition of measurement (maximum 3 hours) |
| Safety variable: FiO2 adjustments during measurement | FiO2 adjustments required, during manipulation or leakage measurement. | 0 to competition of measurement (maximum 3 hours) |
| Safety variable: Circulatory instability | Circulatory instability (bradycardia or hypotension) requiring treatment or adjustment, during manipulation or leakage measurement. | 0 to competition of measurement (maximum 3 hours) |
| Safety variable: Nasal irritation | Nasal irritation requiring treatment or attention, during or after manipulation and leakage measurement. | 0 to competition of measurement (maximum 3 hours) |
| Safety variable: Pneumothorax | Confirmed pneumothorax or air-leak, during manipulation or leakage measurement. | 0 to competition of measurement (maximum 3 hours) |
| Safety variable: Adverse events | Problems related to trial or equipment used, classified as adverse events according to GCP (Good Clinical Practice) | 0 to competition of measurement (maximum 3 hours) |
| Safety variable: Adherence to protocol | Problems related to following study protocol | 0 to competition of measurement (maximum 3 hours) |
| Safety variable: Problems with equipment | Problems related to study equipment | 0 to competition of measurement (maximum 3 hours) |
| Stockholm |
| 171 76 |
| Sweden |
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |